These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 26049951)

  • 1. Cabotegravir long-acting for HIV-1 prevention.
    Andrews CD; Heneine W
    Curr Opin HIV AIDS; 2015 Jul; 10(4):258-63. PubMed ID: 26049951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.
    Blair HA
    Drugs; 2022 Sep; 82(14):1489-1498. PubMed ID: 36255686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor.
    Kovač L; Časar Z
    Expert Opin Ther Pat; 2020 Mar; 30(3):195-208. PubMed ID: 31944142
    [No Abstract]   [Full Text] [Related]  

  • 4. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
    Murray MI; Markowitz M; Frank I; Grant RM; Mayer KH; Hudson KJ; Stancil BS; Ford SL; Patel P; Rinehart AR; Spreen WR; Margolis DA
    HIV Clin Trials; 2018 Aug; 19(4):129-138. PubMed ID: 30445896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
    Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
    Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation and pharmacology of long-acting cabotegravir.
    Trezza C; Ford SL; Spreen W; Pan R; Piscitelli S
    Curr Opin HIV AIDS; 2015 Jul; 10(4):239-45. PubMed ID: 26049948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1.
    McPherson TD; Sobieszczyk ME; Markowitz M
    Expert Opin Investig Drugs; 2018 Apr; 27(4):413-420. PubMed ID: 29633869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of cabotegravir for HIV treatment and prevention.
    Canetti D; Spagnuolo V
    Expert Opin Pharmacother; 2021 Mar; 22(4):403-414. PubMed ID: 33112699
    [No Abstract]   [Full Text] [Related]  

  • 9. Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis.
    Prather C; Jeon C
    Am J Health Syst Pharm; 2022 Oct; 79(21):1898-1905. PubMed ID: 35894204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting injectable cabotegravir for the prevention of HIV infection.
    Clement ME; Kofron R; Landovitz RJ
    Curr Opin HIV AIDS; 2020 Jan; 15(1):19-26. PubMed ID: 31644481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251.
    Andrews CD; Bernard LS; Poon AY; Mohri H; Gettie N; Spreen WR; Gettie A; Russell-Lodrigue K; Blanchard J; Hong Z; Ho DD; Markowitz M
    AIDS; 2017 Feb; 31(4):461-467. PubMed ID: 27902508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.
    Landovitz RJ; Li S; Eron JJ; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Eshleman SH; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Cohen MS; McCauley M; Hendrix CW
    Lancet HIV; 2020 Jul; 7(7):e472-e481. PubMed ID: 32497491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077.
    Tolley EE; Zangeneh SZ; Chau G; Eron J; Grinsztejn B; Humphries H; Liu A; Siegel M; Bertha M; Panchia R; Li S; Cottle L; Rinehart A; Margolis D; Jennings A; McCauley M; Landovitz RJ
    AIDS Behav; 2020 Sep; 24(9):2520-2531. PubMed ID: 32052214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis.
    Pons-Faudoa FP; Sizovs A; Di Trani N; Paez-Mayorga J; Bruno G; Rhudy J; Manohar M; Gwenden K; Martini C; Chua CYX; Varchi G; Marzinke MA; Grattoni A
    J Control Release; 2019 Jul; 306():89-96. PubMed ID: 31136811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.
    Smith J; Bansi-Matharu L; Cambiano V; Dimitrov D; Bershteyn A; van de Vijver D; Kripke K; Revill P; Boily MC; Meyer-Rath G; Taramusi I; Lundgren JD; van Oosterhout JJ; Kuritzkes D; Schaefer R; Siedner MJ; Schapiro J; Delany-Moretlwe S; Landovitz RJ; Flexner C; Jordan M; Venter F; Radebe M; Ripin D; Jenkins S; Resar D; Amole C; Shahmanesh M; Gupta RK; Raizes E; Johnson C; Inzaule S; Shafer R; Warren M; Stansfield S; Paredes R; Phillips AN;
    Lancet HIV; 2023 Apr; 10(4):e254-e265. PubMed ID: 36642087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive value of macaque models of preexposure prophylaxis for HIV prevention.
    García-Lerma JG; McNicholl JM; Heneine W
    Curr Opin HIV AIDS; 2022 Jul; 17(4):179-185. PubMed ID: 35762371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
    Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
    Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis.
    Stellbrink HJ; Hoffmann C
    Curr Opin HIV AIDS; 2018 Jul; 13(4):334-340. PubMed ID: 29746267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date.
    Whitfield T; Torkington A; van Halsema C
    HIV AIDS (Auckl); 2016; 8():157-164. PubMed ID: 27799824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis.
    Shaik JS; Weld ED; Edick S; Fuchs E; Riddler S; Marzinke MA; D'Amico R; Bakshi K; Lou Y; Hendrix C; Han K; Ford SL; Margolis D; Spreen W; Patel P
    Br J Clin Pharmacol; 2022 Feb; 88(4):1667-1678. PubMed ID: 34240467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.